Harmonizome 3.0

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lactate (calcium)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Irinotecan (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Niclosamide (olamine)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Crizotinib (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ivabradine (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the S-Adenosyl-L-methionine (disulfate tosylate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lumateperone (tosylate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Azithromycin (hydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pentamidine (isethionate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Procainamide (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Topotecan (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fedratinib (hydrochloride hydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Esmolol (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rucaparib (phosphate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cysteamine (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Phenytoin (sodium)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Norepinephrine (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Canagliflozin (hemihydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pexidartinib (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cytarabine (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Almonertinib (mesylate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cabozantinib (S-malate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Chlorhexidine (diacetate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the (R)-Verapamil (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methyl aminolevulinate (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bisoprolol (hemifumarate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bestatin (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Benproperine (phosphate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Doxycycline (monohydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Balsalazide (sodium hydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Carbidopa (monohydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Citalopram (hydrobromide)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sivelestat (sodium tetrahydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Berbamine (dihydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Flumatinib (mesylate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Levobupivacaine (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the L-Thyroxine (sodium salt pentahydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cloxacillin (sodium)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Perindopril (erbumine)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fingolimod (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Phenylephrine (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tetracycline (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Benztropine (mesylate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rutin (trihydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Imiquimod (maleate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dapagliflozin ((2S)-1,2-propanediol, hydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Docetaxel (Trihydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Indacaterol (maleate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lenalidomide (hemihydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Atazanavir (sulfate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Omeprazole (sodium)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bosentan (hydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dorzolamide (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Entecavir (monohydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Nafamostat (mesylate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tirabrutinib (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ouabain (Octahydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rimonabant (Hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pyridoxine (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tofacitinib (citrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belumosudil (mesylate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Goserelin (acetate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ropivacaine (hydrochloride monohydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the L-Eflornithine (monohydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lidocaine (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Palmatine (chloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mitoxantrone (dihydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Osimertinib (mesylate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fluvoxamine (maleate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fostamatinib (disodium hexahydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LY-2584702 (tosylate salt)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Quinidine (15% dihydroquinidine)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid (hydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Berberine (chloride hydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pravastatin (sodium)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Imiquimod (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Neratinib (maleate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pasireotide (acetate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Estrone sulfate (potassium)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Idarubicin (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Edoxaban (tosylate monohydrate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Loperamide (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clonidine (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Erdafitinib _MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Selinexor _MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Almonertinib (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vinblastine (sulfate)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Epirubicin (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Doxorubicin (hydrochloride)_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SNU-423 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SW 900 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_RPMI-7951 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_A549 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_LoVo drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_PANC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_A498 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SHP-77 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_COLO 205 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SW480 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_HT-29 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SW48 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SNU-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_LOX-IMVI drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_RKO drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_CFPAC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_AsPC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SW1417 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_LS 180 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_A-172 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SK-MEL-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_H4 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_HepG2/C3A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_HEC-1-A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_BT-474 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SW 1271 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_Panc 03.27 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_CHP-212 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_C32 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_SW 1088 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_hTERT-HPNE drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_A-427 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_KATO III drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_C-33 A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_J82 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_HOP62 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_AN3 CA drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_NCI-H460 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pitavastatin (Calcium)_HCT15 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From DGIdb Drug Targets 2026

interacting proteins for the PITAVASTATIN CALCIUM drug from theDGIdb Drug Targets 2026 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium-mediated signaling using intracellular calcium source biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium-mediated signaling using extracellular calcium source biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-induced calcium release activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium/calmodulin-dependent/calcium-dependent protein kinase protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium release-activated calcium channel protein protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From GO Biological Process Annotations 2023

genes participating in the negative regulation of calcium ion transmembrane transport via high voltage-gated calcium channel biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the regulation of calcium ion transmembrane transport via high voltage-gated calcium channel biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the calcium-mediated signaling using intracellular calcium source biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the calcium ion transmembrane transport via high voltage-gated calcium channel biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Biological Process Annotations 2023

genes participating in the calcium-mediated signaling using extracellular calcium source biological process from the curated GO Biological Process Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the calcium-induced calcium release activity molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the P-type calcium transporter activity involved in regulation of postsynaptic cytosolic calcium ion concentration molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the P-type calcium transporter activity involved in regulation of presynaptic cytosolic calcium ion concentration molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From GO Molecular Function Annotations 2023

genes performing the calcium:monoatomic cation antiporter activity involved in regulation of postsynaptic cytosolic calcium ion concentration molecular function from the curated GO Molecular Function Annotations 2023 dataset.

From SynGO Synaptic Gene Annotations

genes associated with the synaptic term ATPase-coupled calcium ion transmembrane transporter activity involved in regulation of postsynaptic cytosolic calcium levels from the SynGO Synaptic Gene Annotations dataset.

From SynGO Synaptic Gene Annotations

genes associated with the synaptic term ATPase-coupled calcium ion transmembrane transporter activity involved in regulation of presynaptic cytosolic calcium levels from the SynGO Synaptic Gene Annotations dataset.

From SynGO Synaptic Gene Annotations

genes associated with the synaptic term voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels from the SynGO Synaptic Gene Annotations dataset.

From SynGO Synaptic Gene Annotations

genes associated with the synaptic term calcium ion binding involved in regulation of presynaptic cytosolic calcium levels from the SynGO Synaptic Gene Annotations dataset.

From SynGO Synaptic Gene Annotations

genes associated with the synaptic term calcium ion binding involved in regulation of postsynaptic cytosolic calcium levels from the SynGO Synaptic Gene Annotations dataset.

From SynGO Synaptic Gene Annotations

genes associated with the synaptic term calcium:cation antiporter activity involved in regulation of postsynaptic cytosolic calcium ion levels from the SynGO Synaptic Gene Annotations dataset.

From GO Biological Process Annotations 2025

genes participating in the negative regulation of calcium ion transmembrane transport via high voltage-gated calcium channel biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the regulation of calcium ion transmembrane transport via high voltage-gated calcium channel biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the calcium ion transmembrane transport via high voltage-gated calcium channel biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Biological Process Annotations 2025

genes participating in the positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel biological process from the curated GO Biological Process Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the calcium-induced calcium release activity molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the P-type calcium transporter activity involved in regulation of postsynaptic cytosolic calcium ion concentration molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the P-type calcium transporter activity involved in regulation of presynaptic cytosolic calcium ion concentration molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From GO Molecular Function Annotations 2025

genes performing the calcium:monoatomic cation antiporter activity involved in regulation of postsynaptic cytosolic calcium ion concentration molecular function from the curated GO Molecular Function Annotations 2025 dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical pitavastatin from the curated CTD Gene-Chemical Interactions dataset.

From DrugBank Drug Targets

interacting proteins for the Pitavastatin drug from the curated DrugBank Drug Targets dataset.

From GAD Gene-Disease Associations

genes associated with the disease pitavastatin pharmacokinetics in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GeneRIF Biological Term Annotations

genes co-occuring with the biological term pitavastatin in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.

From ClinVar Gene-Phenotype Associations 2025

genes associated with the Pitavastatin response - Metabolism/ phenotype from the curated ClinVar Gene-Phenotype Associations 2025 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the PITAVASTATIN drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the PITAVASTATIN MAGNESIUM drug from theDGIdb Drug Targets 2026 dataset.

From DGIdb Drug Targets 2026

interacting proteins for the PITAVASTATIN SODIUM drug from theDGIdb Drug Targets 2026 dataset.

From COSMIC Cell Line Gene CNV Profiles

genes with high or low copy number in MIA-PACA-2 relative to other cell lines from the COSMIC Cell Line Gene CNV Profiles dataset.

From COSMIC Cell Line Gene Mutation Profiles

genes mutated in the MIA-PACA-2 cell line from the COSMIC Cell Line Gene Mutation Profiles dataset.

From GDSC Cell Line Gene Expression Profiles

genes with high or low expression in MIA-PaCa-2 relative to other cell lines from the GDSC Cell Line Gene Expression Profiles dataset.

From GeneRIF Biological Term Annotations

genes co-occuring with the biological term paca in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.

From Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles

genes with high or low copy number in MIA PACA-2 relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene CNV Profiles dataset.

From Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Expression Profiles

genes with high or low expression in MIA PACA-2 relative to other cell lines from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Expression Profiles dataset.

From Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Mutation Profiles

genes mutated in the MIA PACA-2 cell line from the Klijn et al., Nat. Biotechnol., 2015 Cell Line Gene Mutation Profiles dataset.

From TISSUES Text-mining Tissue Protein Expression Evidence Scores

proteins co-occuring with the tissue paca-44 cell in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores dataset.

From Sanger Dependency Map Cancer Cell Line Proteomics

proteins associated with the cell line MIA-PaCa-2 from the Sanger Dependency Map Cancer Cell Line Proteomics dataset.

From TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025

proteins co-occuring with the tissue PaCa-44 cell in abstracts of biomedical publications from the TISSUES Text-mining Tissue Protein Expression Evidence Scores 2025 dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Arbutin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methotrexate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rimonabant_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ponatinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vortioxetine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clobetasol propionate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bexarotene_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Retinoic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dexamethasone_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bortezomib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sulfisoxazole_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Valdecoxib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tazarotene_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Erlotinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Captopril_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Carbamazepine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oleic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the BI-78D3_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Irinotecan_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Aprepitant_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the palbociclib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Capmatinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 8-Hydroxyquinoline_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the BAY1125976_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NVP-BHG712_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the venetoclax_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Salicylic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD2858_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sapanisertib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Homoharringtonine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ixazomib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lonafarnib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Encorafenib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the APTO-253_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Demeclocycline_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lucanthone_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dabrafenib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Volasertib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tucidinostat_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Celecoxib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the TAK-733_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the RMC-6236_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Amsacrine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pralsetinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vemurafenib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Temuterkib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ETC-206_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bimiralisib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the SBI-0640756_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AT7519_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pimitespib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the GSK1059615_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the (S)-Crizotinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Furosemide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Everolimus_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tomivosertib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tubulin inhibitor 6_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pyridoxine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Abemaciclib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gemfibrozil_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lipoic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Abiraterone acetate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Futibatinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Malotilate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ritonavir_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Proglumide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ralimetinib dimesylate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Panobinostat_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ferulic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Riluzole hydrochloride_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mifepristone_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the vincristine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Drospirenone_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pimozide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cilostazol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Raltitrexed_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gallic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Delamanid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glycyrrhizic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dexmedetomidine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Adenosine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the XRK3F2_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the IQ 1_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Peretinoin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mebendazole_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cepharanthine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LJI308_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Flutamide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Berbamine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Binimetinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Talc_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fenofibrate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Piroxicam_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD1390_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Artesunate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ciclopirox_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cyclosporin A_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fusidic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the DTP3_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Baicalin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Minodronic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ribociclib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Brivudine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dihydroartemisinin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Econazole_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 5-Fluorouracil_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 9-ING-41_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Darolutamide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tranilast_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Asciminib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Acetazolamide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oxaprozin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Thymopentin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Verapamil_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Meloxicam_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belinostat_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Voriconazole_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hesperidin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sonidegib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methylprednisolone succinate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the PH-797804_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Neratinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ornidazole_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Artemether_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tucatinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Zileuton_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pioglitazone_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pentagastrin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Regorafenib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Megestrol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rifaximin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Filgotinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dapagliflozin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Altretamine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clotrimazole_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vandetanib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Quinestrol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fluvoxamine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clopidogrel_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Omeprazole_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 5-Azacytidine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ataluren_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hexylresorcinol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the c-Kit-IN-1_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Terfenadine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tolmetin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Nevirapine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Resveratrol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Uridine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Monocrotaline_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Roxadustat_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Larotrectinib sulfate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tadalafil_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ixazomib citrate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Penfluridol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the MK-8353_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fumaric acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Mozavaptan_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dimethyl fumarate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Canagliflozin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Decitabine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sulfatinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Simotinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cytarabine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the crizotinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Idoxuridine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Radotinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Fulvestrant_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bicalutamide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Nimesulide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Capivasertib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hydroxyfasudil_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bendamustine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trametinib (DMSO_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ML264_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Adagrasib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pemetrexed_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belzutifan_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Diphenhydramine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD-8055_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trametinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Eplerenone_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cobimetinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Isocorydine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lapatinib ditosylate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Anastrozole_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the MK-3903_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vismodegib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tolcapone_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sunitinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sildenafil_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ligustrazine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Olanzapine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ULK-101_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ranolazine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Macitentan_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vitamin K4_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Oxaliplatin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Silodosin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Darinaparsin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Folic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Menadione_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Dinaciclib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sodium Salicylate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tirabrutinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Tofacitinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the NG25_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Infigratinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Sinomenine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Aspirin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LB-100_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Elimusertib hydrochloride_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Harringtonine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gemcitabine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the ERK5-IN-2_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Posaconazole_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the EX229_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Cinacalcet_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Relugolix_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Daidzin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the PF-06260933_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Brimonidine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Busulfan_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Methylthiouracil_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Belumosudil_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Finasteride_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bimatoprost_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Lopinavir_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Allopurinol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ivermectin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pemigatinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Budesonide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Medroxyprogesterone acetate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Thymol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bergenin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rapamycin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Larotrectinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Betamethasone dipropionate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Anethole trithione_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Apalutamide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Paclitaxel_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Digitoxin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Orlistat_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Allantoin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the TAK-901_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Pentoxifylline_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Acetohexamide_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the DT-061_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the olaparib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Alpelisib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Naproxen_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Adenine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Triamcinolone_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Afatinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Triclosan_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Vilanterol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trifluridine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Ipatasertib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the γ-Oryzanol_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Hydroxyurea_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Glasdegib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Plicamycin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Trimetrexate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Torkinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the CP21R7_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Auranofin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Elagolix sodium_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Verteporfin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Saquinavir_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the AZD-7648_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the OTS514_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 4EGI-1_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the HI-TOPK-032_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Diammonium Glycyrrhizinate_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bestatin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Temsirolimus_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Daptomycin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Gefitinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Entrectinib_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Aliskiren_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the LY2090314_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Clofarabine_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the BI-3406_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Erythromycin_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Bentamapimod_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Rosiglitazone_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the Docetaxel_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Rummagene Transcription Factor Associations 2026

target genes of the PMC6483366-pcbi.1006953.s026.xlsx-PACA-OGM_PTF1A transcription factor from the Rummagene Transcription Factor Associations 2026 dataset.

From Biocarta Pathways

proteins participating in the calcium signaling by hbx of hepatitis b virus pathway from the Biocarta Pathways dataset.

From Biocarta Pathways

proteins participating in the control of skeletal myogenesis by hdac and calcium/calmodulin-dependent kinase (camk) pathway from the Biocarta Pathways dataset.

From ClinVar Gene-Phenotype Associations

genes associated with the Immune dysfunction with T-cell inactivation due to calcium entry defect 1 phenotype from the curated ClinVar Gene-Phenotype Associations dataset.

From ClinVar Gene-Phenotype Associations

genes associated with the Immune dysfunction with T-cell inactivation due to calcium entry defect 2 phenotype from the curated ClinVar Gene-Phenotype Associations dataset.

From CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the calcium pantothenate-4189 small molecule perturbation from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the calcium folinate-4725 small molecule perturbation from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the calcium pantothenate-1311 small molecule perturbation from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the calcium pantothenate-4775 small molecule perturbation from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the calcium pantothenate-3248 small molecule perturbation from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the calcium folinate-7401 small molecule perturbation from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the calcium folinate-3442 small molecule perturbation from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the calcium folinate-3703 small molecule perturbation from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From CMAP Signatures of Differentially Expressed Genes for Small Molecules

genes differentially expressed following the calcium folinate-2579 small molecule perturbation from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.

From COMPARTMENTS Curated Protein Localization Evidence Scores

proteins localized to the calcium- and calmodulin-dependent protein kinase complex cellular component from the COMPARTMENTS Curated Protein Localization Evidence Scores dataset.

From COMPARTMENTS Curated Protein Localization Evidence Scores

proteins localized to the calcium ion-transporting atpase complex cellular component from the COMPARTMENTS Curated Protein Localization Evidence Scores dataset.

From COMPARTMENTS Curated Protein Localization Evidence Scores

proteins localized to the voltage-gated calcium channel complex cellular component from the COMPARTMENTS Curated Protein Localization Evidence Scores dataset.

From COMPARTMENTS Curated Protein Localization Evidence Scores

proteins localized to the calcium channel complex cellular component from the COMPARTMENTS Curated Protein Localization Evidence Scores dataset.

From COMPARTMENTS Text-mining Protein Localization Evidence Scores

proteins co-occuring with the calcium- and calmodulin-dependent protein kinase complex cellular component in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores dataset.

From COMPARTMENTS Text-mining Protein Localization Evidence Scores

proteins co-occuring with the voltage-gated calcium channel complex cellular component in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores dataset.

From COMPARTMENTS Text-mining Protein Localization Evidence Scores

proteins co-occuring with the calcium channel complex cellular component in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical Calcium, Dietary from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical Calcium Ionophores from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical Calcium Carbonate from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical Calcium from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical calcium phosphate from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical Calcium Chloride from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical calcium bicarbonate from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical calcium silicate from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical calcium heparin from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical Calcium Channel Blockers from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Disease Associations

genes/proteins associated with the disease Immune dysfunction with T-cell inactivation due to calcium entry defect 1 from the curated CTD Gene-Disease Associations dataset.

From CTD Gene-Disease Associations

genes/proteins associated with the disease Immune dysfunction with T-cell inactivation due to calcium entry defect 2 from the curated CTD Gene-Disease Associations dataset.

From dbGAP Gene-Trait Associations

genes associated with the trait Calcium-Binding Proteins in GWAS and other genetic association datasets from the dbGAP Gene-Trait Associations dataset.

From dbGAP Gene-Trait Associations

genes associated with the trait Calcium in GWAS and other genetic association datasets from the dbGAP Gene-Trait Associations dataset.

From DISEASES Text-mining Gene-Disease Association Evidence Scores

genes co-occuring with the disease calcium metabolism disease in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores dataset.

From DrugBank Drug Targets

interacting proteins for the Calcium drug from the curated DrugBank Drug Targets dataset.

From GAD Gene-Disease Associations

genes associated with the disease calcium homeostasis and peripheral bone density in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease atherosclerosis, carotid coronary artery calcium, intimal medial thickness in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease calcium in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease coronary artery calcium in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease calcium-binding proteins in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease calcium oxalate stone disease in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease calcium excretion in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease serum total and ionized calcium concentration in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease calcium oxalate stones in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease calcium metabolism disorders in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease bone density; calcium; fractures, nonvertebral; milk intolerance in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease total serum calcium in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GAD Gene-Disease Associations

genes associated with the disease calcium nephrolithiasis in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.

From GeneRIF Biological Term Annotations

genes co-occuring with the biological term calcium in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of high voltage-gated calcium channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of mitochondrial calcium ion concentration biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of ryanodine-sensitive calcium-release channel activity by adrenergic receptor signaling pathway involved in positive regulation of cardiac muscle contraction biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion-dependent exocytosis of neurotransmitter biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium activated galactosylceramide scrambling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of release of sequestered calcium ion into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium-independent cell-cell adhesion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium-mediated signaling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium ion-dependent exocytosis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of ryanodine-sensitive calcium-release channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium activated phospholipid scrambling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium ion-dependent exocytosis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the wnt signaling pathway, calcium modulating pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion transport into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium-dependent cell-cell adhesion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium-independent cell-matrix adhesion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium ion transmembrane transporter activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium:sodium antiporter activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium ion import biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of cytosolic calcium ion concentration biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium ion import into sarcoplasmic reticulum biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium-independent cell-cell adhesion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of cardiac muscle contraction by calcium ion signaling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the release of sequestered calcium ion into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium ion import into sarcoplasmic reticulum biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of transcription from rna polymerase ii promoter in response to calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion import into cell biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of cytosolic calcium ion concentration biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of intracellular calcium activated chloride channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of endoplasmic reticulum calcium ion concentration biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the activation of store-operated calcium channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium-independent cell-cell adhesion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium-transporting atpase activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium:sodium antiporter activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion transmembrane import into mitochondrion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of large conductance calcium-activated potassium channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of cytosolic calcium ion concentration involved in phospholipase c-activating g-protein coupled signaling pathway biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium ion transport into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium-mediated signaling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of release of sequestered calcium ion into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the sarcoplasmic reticulum calcium ion transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of endoplasmic reticulum calcium ion concentration biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the store-operated calcium entry biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium ion transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the endoplasmic reticulum calcium ion homeostasis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium ion-dependent exocytosis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the mitochondrial calcium ion homeostasis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion import across plasma membrane biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the mitochondrial calcium ion transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the release of sequestered calcium ion into cytosol by sarcoplasmic reticulum biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of ryanodine-sensitive calcium-release channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of store-operated calcium channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium ion import biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the smooth endoplasmic reticulum calcium ion homeostasis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of ryanodine-sensitive calcium-release channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the golgi calcium ion transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of voltage-gated calcium channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion export biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium ion transmembrane transporter activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium-transporting atpase activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of intracellular calcium activated chloride channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion transmembrane import into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium-dependent cell-cell adhesion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium ion transport into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of release of sequestered calcium ion into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium-mediated signaling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium ion binding biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of calcium ion import biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium activated phosphatidylcholine scrambling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium-dependent cell-matrix adhesion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium ion transport into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of store-operated calcium channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of voltage-gated calcium channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion homeostasis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium activated phosphatidylserine scrambling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium:sodium antiporter activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium ion transmembrane transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium ion transmembrane transporter activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion import into cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium ion-dependent exocytosis of neurotransmitter biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of voltage-gated calcium channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the detection of calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion export from cell biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the cytosolic calcium ion homeostasis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the cytosolic calcium ion transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium-transporting atpase activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of calcium ion transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of store-operated calcium entry biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium ion transmembrane transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion import biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of generation of l-type calcium current biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the sequestering of calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium ion binding biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the cellular response to calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium-mediated signaling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion import into sarcoplasmic reticulum biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of mitochondrial calcium ion concentration biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of sequestering of calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion transport from endoplasmic reticulum to cytosol biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion transport from cytosol to endoplasmic reticulum biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of large conductance calcium-activated potassium channel activity biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the negative regulation of sequestering of calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of skeletal muscle contraction by calcium ion signaling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the response to calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium ion transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the golgi calcium ion homeostasis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the activation of phospholipase a2 activity by calcium-mediated signaling biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the fast, calcium ion-dependent exocytosis of neurotransmitter biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the positive regulation of sequestering of calcium ion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the regulation of calcium-dependent cell-cell adhesion biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion transmembrane transport biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the calcium ion-dependent exocytosis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Biological Process Annotations 2015

genes participating in the cellular calcium ion homeostasis biological process from the curated GO Biological Process Annotations 2015 dataset.

From GO Cellular Component Annotations 2015

proteins localized to the calcium- and calmodulin-dependent protein kinase complex cellular component from the curated GO Cellular Component Annotations 2015 dataset.

From GO Cellular Component Annotations 2015

proteins localized to the calcium ion-transporting atpase complex cellular component from the curated GO Cellular Component Annotations 2015 dataset.

From GO Cellular Component Annotations 2015

proteins localized to the l-type voltage-gated calcium channel complex cellular component from the curated GO Cellular Component Annotations 2015 dataset.

From GO Cellular Component Annotations 2015

proteins localized to the voltage-gated calcium channel complex cellular component from the curated GO Cellular Component Annotations 2015 dataset.

From GO Cellular Component Annotations 2015

proteins localized to the calcium channel complex cellular component from the curated GO Cellular Component Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the large conductance calcium-activated potassium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the intracellular calcium activated chloride channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent cysteine-type endopeptidase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium:sodium antiporter activity involved in regulation of cardiac muscle cell membrane potential molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent phospholipase a2 activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the high voltage-gated calcium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium channel regulator activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent phospholipid binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-independent phospholipase a2 activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent protein serine/threonine phosphatase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the ryanodine-sensitive calcium-release channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-activated potassium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium oxalate binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the small conductance calcium-activated potassium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium activated cation channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the voltage-gated calcium channel activity involved sa node cell action potential molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent protein kinase regulator activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent protein serine/threonine kinase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the store-operated calcium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent protein kinase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium- and calmodulin-regulated 3',5'-cyclic-gmp phosphodiesterase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium ion binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent phospholipase c activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the low voltage-gated calcium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium, potassium:sodium antiporter activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent protein kinase inhibitor activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-transporting atpase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-transporting atpase activity involved in regulation of cardiac muscle cell membrane potential molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent atpase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium sensitive guanylate cyclase activator activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent protein binding molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-independent protein kinase c activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent protein kinase c activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium:cation antiporter activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the voltage-gated calcium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-dependent protein serine/threonine phosphatase regulator activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium channel inhibitor activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium ion transmembrane transporter activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium:sodium antiporter activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the intermediate conductance calcium-activated potassium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the voltage-gated calcium channel activity involved in cardiac muscle cell action potential molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the naadp-sensitive calcium-release channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium-release channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the calcium- and calmodulin-responsive adenylate cyclase activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GO Molecular Function Annotations 2015

genes performing the intracellular ligand-gated calcium channel activity molecular function from the curated GO Molecular Function Annotations 2015 dataset.

From GWAS Catalog SNP-Phenotype Associations

genes associated with the Calcium levels phenotype in GWAS datasets from the GWAS Catalog SNP-Phenotype Associations dataset.

From GWASdb SNP-Disease Associations

genes associated with the disease calcium metabolism disease in GWAS and other genetic association datasets from the GWASdb SNP-Disease Associations dataset.

From GWASdb SNP-Phenotype Associations

genes associated with the abnormality of calcium homeostasis phenotype in GWAS datasets from the GWASdb SNP-Phenotype Associations dataset.

From HMDB Metabolites of Enzymes

interacting proteins for the Calcium metabolite from the curated HMDB Metabolites of Enzymes dataset.

From HPO Gene-Disease Associations

genes associated with the abnormality of urine calcium concentration phenotype by mapping known disease genes to disease phenotypes from the HPO Gene-Disease Associations dataset.

From HPO Gene-Disease Associations

genes associated with the parathormone-independent increased renal tubular calcium reabsorption phenotype by mapping known disease genes to disease phenotypes from the HPO Gene-Disease Associations dataset.

From HPO Gene-Disease Associations

genes associated with the abnormal concentration of calcium in blood phenotype by mapping known disease genes to disease phenotypes from the HPO Gene-Disease Associations dataset.

From HPO Gene-Disease Associations

genes associated with the calcium oxalate nephrolithiasis phenotype by mapping known disease genes to disease phenotypes from the HPO Gene-Disease Associations dataset.

From HPO Gene-Disease Associations

genes associated with the renal calcium wasting phenotype by mapping known disease genes to disease phenotypes from the HPO Gene-Disease Associations dataset.

From HPO Gene-Disease Associations

genes associated with the abnormality of calcium homeostasis phenotype by mapping known disease genes to disease phenotypes from the HPO Gene-Disease Associations dataset.

From HPO Gene-Disease Associations

genes associated with the calcium nephrolithiasis phenotype by mapping known disease genes to disease phenotypes from the HPO Gene-Disease Associations dataset.

From HPO Gene-Disease Associations

genes associated with the abnormality of calcium-phosphate metabolism phenotype by mapping known disease genes to disease phenotypes from the HPO Gene-Disease Associations dataset.

From HuGE Navigator Gene-Phenotype Associations

genes associated with the Calcium Metabolism Disorders phenotype by text-mining GWAS publications from the HuGE Navigator Gene-Phenotype Associations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, T-type, alpha-1 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, L-type, alpha-1C subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Guanylate kinase/L-type calcium channel beta subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Plasma membrane calcium-transporting ATPase 2 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Plasma membrane calcium-transporting ATPase 3 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium/calmodulin-dependent protein kinase II, association-domain protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sarcoplasmic/endoplasmic reticulum calcium ATPase 3 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, T-type, alpha-1I subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Histidine-rich calcium-binding protein protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the EGF-like calcium-binding, conserved site protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium-responsive transcription factor protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, N-type, alpha-1 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Histidine-rich calcium-binding protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, R-type, alpha-1 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, gamma-1 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, gamma subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, gamma-7 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium-dependent secretion activator protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the SPARC/Testican, calcium-binding domain protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel,T-type, alpha-1G subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sodium/potassium/calcium exchanger 5 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sodium/potassium/calcium exchanger 4 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sodium/potassium/calcium exchanger 3 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sodium/potassium/calcium exchanger 2 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium/calmodulin-dependent protein kinase II inhibitor protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium-transporting ATPase type 2C member 1 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium-transporting ATPase type 2C member 2 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, gamma-5 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Plasma membrane calcium-transporting ATPase 4 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Plasma membrane calcium-transporting ATPase 1 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, gamma-6 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Potassium channel, calcium-activated, BK, beta subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, gamma-2 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the EF-Hand 1, calcium-binding site protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sodium/calcium exchanger membrane region protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, alpha-1 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel gamma-like subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the EGF-like calcium-binding domain protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, L-type, alpha-1F subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, L-type, alpha-1D subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, gamma-4 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium binding protein 2 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium-binding protein CAB45 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, P/Q-type, alpha-1 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium channel flower protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, L-type, alpha-1 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, L-type, beta-1 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium signal-modulating cyclophilin ligand protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the TVP18/Calcium channel flower protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, L-type, beta subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Potassium channel, calcium-activated, SK protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium-binding and spermatid-specific protein 1 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, L-type, beta-3 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, alpha-2/delta subunit, conserved region protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, L-type, beta-2 subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, T-type, alpha-1H subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Plasma membrane calcium transporting P-type ATPase, C-terminal protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the EF-hand calcium-binding domain-containing protein 6 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sodium/potassium/calcium exchanger 1 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium homeostasis modulator protein 2 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium homeostasis modulator protein 3 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Calcium homeostasis modulator protein 1 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Voltage-dependent calcium channel, L-type, alpha-1S subunit protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Sodium/calcium exchanger, isoform 1 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From InterPro Predicted Protein Domain Annotations